1-15 of 15
Hwan Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Open Access
Dong Kwon Kim, Chun-Bong Synn, Wongeun Lee, Ha-Ni Jo, Chai Young Lee, Seul Lee, Joon Yeon Hwang, Youngtaek Kim, Seong-san Kang, Sujeong Baek, Kwangmin Na, Seung Min Yang, Mi Hyun Kim, Heekyung Han, Yu Jin Han, Jae Hwan Kim, So Young Park, Young Joon Park, Gang-Taik Lee, Su-Jin Choi, Jie-Ohn Sohn, Sang-Kyu Ye, Jii Bum Lee, Sun Min Lim, Min Hee Hong, Kyoung-Ho Pyo, Byoung Chul Cho
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2025) 24 (3): 354–369.
https://doi.org/10.1158/1535-7163.MCT-24-0501
Published: 04 March 2025
View articletitled, Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Open the PDF for Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

Abstract C075: A first-in-class and highly selective SHP1 allosteric inhibitor exhibits robust anti-tumor immunity and synergizes with PD-1 blockade

Free
Jun Gyu Kim, Ki Moon Ryu, Mi Yeon Jang, Jongho Cho, Dajeong Kim, Dae Hyeon Seong, Kyu Hwan Kim, Ik-Soo Jang, Jeong Yoon Shin, Hong Sik Han, Joon Yonug Hwang, Dae Young Lee, Chae Lim Ryu, Song Yi Lee, Tae-Dong Han, SeungMin Yang, Hyounmie Doh
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C075.
https://doi.org/10.1158/1535-7163.TARG-23-C075
Published: 01 December 2023
View articletitled, Abstract C075: A first-in-class and highly selective SHP1 allosteric inhibitor exhibits robust anti-tumor immunity and synergizes with PD-1 blockade
Journal Articles

Abstract B017: Clinical utility of next generation sequencing in advanced colorectal cancer: The earlier the better

Free
Ho Jung An, Hyunho Kim, Hyung Soon Park, Hyeon-Min Cho, Bong-Hyeon Kye, Ri Na Yoo, Ji-Yeon Moon, Sung Hwan Kim, Jonghoon Lee, Hyo Chun Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B017.
https://doi.org/10.1158/1535-7163.TARG-23-B017
Published: 01 December 2023
View articletitled, Abstract B017: Clinical utility of next generation sequencing in advanced colorectal cancer: The earlier the better
Journal Articles

Improving Theranostic Gallium-68/Lutetium-177–Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer

Available to Purchase
Byoung Se Lee, Min Hwan Kim, So Young Chu, Woon Jung Jung, Hyeon Jin Jeong, Kyongkyu Lee, Hyeon Seok Kim, Mi Hyun Kim, Hee Seup Kil, Sang Jin Han, Yong Jin Lee, Kyo Chul Lee, Sang Moo Lim, Dae Yoon Chi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12): 2410–2419.
https://doi.org/10.1158/1535-7163.MCT-21-0251
Published: 03 December 2021
View articletitled, Improving Theranostic Gallium-68/Lutetium-177–Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer
Open the PDF for Improving Theranostic Gallium-68/Lutetium-177–Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract P234: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer

Free
Melissa R. Junttila, Jason E. Long, Robert Warne, Sunghwan Kim, Younho Lee, Hwan Kim, Juhee Kang, Jiyoon Seok, Jihye Yoo, Youngyi Lee, Dong-Hyuk Seo Seo, Jung Beom Son, Daekwon Kim, Hwan Geun Choi, Nam Doo Kim, Tatiana Zavorotinskaya, Chelsea Chan, Matthew Panuwat, Jessica Sun, Jae H. Chang, Lori S. Friedman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P234.
https://doi.org/10.1158/1535-7163.TARG-21-P234
Published: 01 December 2021
View articletitled, Abstract P234: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer
Journal Articles

Abstract B054: The synergistic effect of PLAG on the antitumor efficacy of AC-regimen via alleviating neutrophil tumor infiltration on breast tumor xenograft model

Free
GUEN TAE KIM, SUN YOUNG YOON, KI-YOUNG SOHN, MYUNG-HWAN KIM, JAE WHA KIM
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B054.
https://doi.org/10.1158/1535-7163.TARG-19-B054
Published: 01 December 2019
View articletitled, Abstract B054: The synergistic effect of PLAG on the antitumor efficacy of AC-regimen via alleviating neutrophil tumor infiltration on breast tumor xenograft model
Journal Articles

Abstract C037: Anti-metastatic effect of PLAG via interference of neutrophil elastase/PAR2/EGFR signaling on A549 lung cancer orthotopic implantation model

Free
GUEN TAE KIM, SUN YOUNG YOON, KI-YOUNG SOHN, MYUNG-HWAN KIM, JAE WHA KIM
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C037.
https://doi.org/10.1158/1535-7163.TARG-19-C037
Published: 01 December 2019
View articletitled, Abstract C037: Anti-metastatic effect of PLAG via interference of neutrophil elastase/PAR2/EGFR signaling on A549 lung cancer orthotopic implantation model
Journal Articles

Abstract A070: A phase 1/2a, open-label, dose-escalation study of EC-18 in patients with metastatic breast cancer for the prevention of chemotherapy-induced neutropenia

Free
Sung-Bae Kim, Myung-Hwan Kim
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A070.
https://doi.org/10.1158/1535-7163.TARG-19-A070
Published: 01 December 2019
View articletitled, Abstract A070: A phase 1/2a, open-label, dose-escalation study of EC-18 in patients with metastatic breast cancer for the prevention of chemotherapy-induced neutropenia
Journal Articles

Abstract B002: Discovery of selective and potent EGFR kinase inhibitors for exon20 insertion mutations

Free
Sunghwan Kim, Younho Lee, Hwan Kim, Juhee Kang, Jiyoon Seok, Kyung-Ah Seo, Jaeyoung Ahn, Hee-Bum Kang, Sun-Hwa Lee, Jung Beom Son, Hwan Geun Choi, Nam Doo Kim
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B002.
https://doi.org/10.1158/1535-7163.TARG-19-B002
Published: 01 December 2019
View articletitled, Abstract B002: Discovery of selective and potent EGFR kinase inhibitors for exon20 insertion mutations
Journal Articles

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines

Free
Sung-Moo Kim, Hwan Kim, Kang Won Jang, Min Hwan Kim, Jinyoung Sohn, Mi Ran Yun, Han Na Kang, Chan Woo Kang, Hye Ryun Kim, Sun Min Lim, Yong Wha Moon, Joo Hang Kim, Soonmyung Paik, Byoung Chul Cho
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (7): 1627–1636.
https://doi.org/10.1158/1535-7163.MCT-15-0375
Published: 05 July 2016
View articletitled, EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines
Open the PDF for EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines in another window
Includes: Supplementary data
Journal Articles

Abstract B50: Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation

Free
Min Hwan Kim, Joon Kim
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B50.
https://doi.org/10.1158/1535-7163.TARG-15-B50
Published: 01 December 2015
View articletitled, Abstract B50: Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation
Journal Articles

Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma

Free
Chan Woo Kang, Kang Won Jang, Jinyoung Sohn, Sung-Moo Kim, Kyoung-Ho Pyo, Hwan Kim, Mi Ran Yun, Han Na Kang, Hye Ryun Kim, Sun Min Lim, Yong Wha Moon, Soonmyung Paik, Dae Joon Kim, Joo Hang Kim, Byoung Chul Cho
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (10): 2238–2248.
https://doi.org/10.1158/1535-7163.MCT-15-0350
Published: 05 October 2015
View articletitled, Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
Open the PDF for Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism

Free
Siwang Yu, Guoxiang Shen, Tin Oo Khor, Jung-Hwan Kim, Ah-Ng Tony Kong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (9): 2609–2620.
https://doi.org/10.1158/1535-7163.MCT-07-2400
Published: 11 September 2008
View articletitled, Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
Open the PDF for Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism in another window
Journal Articles

Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2

Free
Changjiang Xu, Xiaoling Yuan, Zui Pan, Guoxiang Shen, Jung-Hwan Kim, Siwang Yu, Tin Oo Khor, Wenge Li, Jianjie Ma, Ah-Ng Tony Kong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (8): 1918–1926.
https://doi.org/10.1158/1535-7163.MCT-05-0497
Published: 23 August 2006
View articletitled, Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2
Open the PDF for Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2 in another window
Journal Articles

The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor–positive and estrogen receptor–negative human breast cancers

Free
Heekyoung Chung, Ji-Youn Jung, Sung-Dae Cho, Kyung-A Hong, Hyun-Jun Kim, Dong-Hui Shin, Hwan Kim, Hea Ok Kim, Dae Hong Shin, Hyuk Woo Lee, Lak Shin Jeong, Gu Kong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (3): 685–692.
https://doi.org/10.1158/1535-7163.MCT-05-0245
Published: 16 March 2006
View articletitled, The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor–positive and estrogen receptor–negative human breast cancers
Open the PDF for The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor–positive and estrogen receptor–negative human breast cancers in another window